Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: DRUG: dovitinib (TKI258)|DRUG: fluvoxamine
Sponsor: Novartis Pharmaceuticals